Effective responses to the COVID-19 pandemic require reliable estimates of actual cases and deaths, and models that incorporate behavioral factors including differential priorities for allocating limited testing capacity, heterogeneous risk perceptions and resulting contact reductions, improved treatment, and adherence fatigue. We develop a behavioral dynamic model integrating these factors with asymptomatic transmission, disease acuity, and hospital capacity. Using a hierarchical Bayesian framework we estimate the model parameters with a panel dataset spanning all 91 nations with reliable testing data. Cumulative cases and deaths through 30 October 2020 are estimated to be 8.5 and 1.4 times greater than official reports, yielding an overall infection fatality rate (IFR) of 0.48%, with wide variation across nations and significant decline in IFR over time. Adherence fatigue is estimated to have increased cumulative cases by 61% through October 2020. Scenarios through March 2021 show modest policy interventions and behavior change could reduce cumulative cases ≈18%. The model endogenously generates the multiple waves of infection and mortality observed in many nations as behavioral responses to perceived risk cause the reproduction number to fluctuate around 1, but with death rates that vary by two orders of magnitude depending on responsiveness to perceived risks.
Human Challenge Trials (HCTs) are a potential method to accelerate development of vaccines and therapeutics. However, HCTs for COVID-19 pose ethical and practical challenges, in part due to the unclear and developing risks. In this paper, we introduce an interactive model for exploring some risks of a SARS-COV-2 dosing study, a prerequisite for any COVID-19 challenge trials. The risk estimates we use are based on a Bayesian evidence synthesis model which can incorporate new data on infection fatality rates (IFRs) to patients, and infer rates of hospitalization. We have also created a web tool to explore risk under different study design parameters and participant scenarios. Finally, we use our model to estimate individual risk, as well as the overall mortality and hospitalization risk in a dosing study. Based on the Bayesian model we expect IFR for someone between 20 and 30 years of age to be 17.5 in 100,000, with 95% uncertainty interval from 12.8 to 23.6. Using this estimate, we find that a simple 50-person dosing trial using younger individuals has a 99.1% (95% CI: 98.8% to 99.4%) probability of no fatalities, and a 92.8% (95% CI: 90.3% to 94.6%) probability of no cases requiring hospitalization. However, this IFR will be reduced in an HCT via screening for comorbidities, as well as providing medical care and aggressive treatment for any cases which occur, so that with stronger assumptions, we project the risk to be as low as 3.1 per 100,000, with a 99.85% (95% CI: 99.7% to 99.9%) chance of no fatalities, and a 98.7% (95% CI: 97.4% to 99.3%) probability of no cases requiring hospitalization.
Fine scale delineation of epitopes recognized by the antibody response to SARS-CoV-2 infection will be critical to understanding disease heterogeneity and informing development of safe and effective vaccines and therapeutics. The Serum Epitope Repertoire Analysis (SERA) platform leverages a high diversity random bacterial display library to identify epitope binding specificities with single amino acid resolution. We applied SERA broadly, across human, viral and viral strain proteomes in multiple cohorts with a wide range of outcomes from SARS-CoV-2 infection. We identify dominant epitope motifs and profiles which effectively classify COVID-19, distinguish mild from severe disease, and relate to neutralization activity. We identify a repertoire of epitopes shared by SARS-CoV-2 and endemic human coronaviruses and determine that a region of amino acid sequence identity shared by the SARS-CoV-2 furin cleavage site and the host protein ENaC-alpha is a potential cross-reactive epitope. Finally, we observe decreased epitope signal for mutant strains which points to reduced antibody response to mutant SARS-CoV-2. Together, these findings indicate that SERA enables high resolution of antibody epitopes that can inform data-driven design and target selection for COVID-19 diagnostics, therapeutics and vaccines.
Background: Whether diabetes is associated with COVID-19-related mortality remains unclear. Methods: In this retrospective case-series study we examined the risk of death associated with self-reported diabetes in symptomatic adult patients with laboratory-confirmed COVID-19 who were identified through the System of Epidemiological Surveillance of Viral Respiratory Disease in Mexico from January 1 through November 4, 2020. Survival time was right-censored at 28 days of follow-up. Results: Among 757,210 patients with COVID-19 included in the study, 120,476 (16%) had diabetes and 80,616 died. Patients with diabetes had a 49% higher relative risk of death than those without diabetes (Cox proportional-hazard ratio; 1.49 (95% confidence interval [CI], 1.47-1.52), adjusting for age, sex, smoking habit, obesity, hypertension, immunodeficiency, and cardiovascular, pulmonary, and chronic renal disease. The relative risk of death associated with diabetes decreased with age (P=0.004). The hazard ratios were 1.66 (1.58-1.74) in outpatients and 1.14 (1.12-1.16) in hospitalized patients. The 28-day survival for inpatients with and without diabetes was, respectively, 73.5% and 85.2% for patients 20-39 years of age; 66.6% and 75.9% for patients 40-49 years of age; 59.4% and 66.5% for patients 50-59 years of age; 50.1% and 54.6% for patients 60-69 years of age; 42.7% and 44.6% for patients 70-79 years of age; and 38.4% and 39.0% for patients 80 years of age or older. In patients without COVID-19 (878,840), the adjusted hazard ratio for mortality was 1.78 (1.73-1.84). Conclusion: In symptomatic adult patients with COVID-19 in Mexico, diabetes was associated with higher mortality. This association decreased with age.
Background The novel coronavirus, SARS-CoV-2, has increased the burden on healthcare systems already strained by a high incidence of tuberculosis (TB) as co-infection and dual presentation are occurring in syndemic settings. We aimed to understand the interaction between these diseases by profiling COVID-19 gene expression signatures on RNA-sequencing data from TB-infected individuals. Methods We performed a systematic review and patient-level meta-analysis by querying PubMed and pre-print servers to derive eligible COVID-19 gene expression signatures from human whole blood (WB), PBMCs or BALF studies. A WB influenza dataset served as a control respiratory disease signature. Three large TB RNA-seq datasets, comprising multiple cohorts from the UK and Africa and consisting of TB patients across the disease spectrum, were chosen to profile these signatures. Putative COVID-19 risk scores were generated for each sample in the TB datasets using the TBSignatureProfiler package. Risk was stratified by time to TB diagnosis in progressors and contacts of pulmonary and extra-pulmonary TB. An integrative analysis between TB and COVID-19 single-cell RNA-seq data was performed and a population-level meta-analysis was conducted to identify shared gene ontologies between the diseases and their relative enrichment in COVID-19 disease severity states. Results 35 COVID-19 gene signatures from nine eligible studies comprising 98 samples were profiled on TB RNA-seq data from 1181 samples from 853 individuals. 25 signatures had significantly higher COVID-19 risk in active TB (ATB) compared with latent TB infection (p <0.005), 13 of which were validated in two independent datasets. FCN1- and SPP1-expressing macrophages enriched in BALF during severe COVID-19 were identified in circulation during ATB. Shared perturbed ontologies included antigen presentation, epigenetic regulation, platelet activation, and ROS/RNS production were enriched with increasing COVID-19 severity. Finally, we demonstrate that the overlapping transcriptional responses may complicate development of blood-based diagnostic signatures of co-infection. Interpretation Our results identify shared dysregulation of immune responses in COVID-19 and TB as a dual risk posed by co-infection to COVID-19 severity and TB disease progression. These individuals should be followed up for TB in the months subsequent to SARS-CoV-2 diagnosis.
A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia - Condition: COVID-19
Intervention: Drug: Nafamostat Mesilate
Sponsor: Chong Kun Dang Pharmaceutical
Not yet recruiting
Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults - Condition: COVID-19
Interventions: Drug: AZD7442; Drug: Placebo
Sponsors: AstraZeneca; QuintilesIMS
Not yet recruiting
Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. - Condition: COVID-19
Interventions: Drug: AZD7442; Drug: Placebo
Sponsors: AstraZeneca; QuintilesIMS
Not yet recruiting
Effectiveness and Safety of Rhea Health Tone® as add-on Therapy for COVID-19 in Hospitalized Adults in Indonesia - Condition: Covid19
Intervention: Dietary Supplement: Rhea Health Tone®
Sponsors: Universitas Padjadjaran; PT. Rhea Pharmaceutical Sciences Indonesia; Prodia Diacro Laboratories P.T.
Not yet recruiting
Fase I Clinical Trial on NK Cells for COVID-19 - Conditions: Covid19; Sars-cov 2
Intervention: Biological: Natural Killer Cells infusion
Sponsor: Hospital de Clinicas de Porto Alegre
Not yet recruiting
A Phase Ⅱ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells) - Condition: COVID-19
Interventions: Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen; Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen; Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen; Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen; Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen; Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen; Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen; Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen; Biological: Low-dose placebo (18-59 years) & Two dose regimen; Biological: Low-dose placebo (18-59 years) & Three dose regimen; Biological: High-dose placebo (18-59 years) & Two dose regimen; Biological: High-dose placebo (18-59 years) & Three dose regimen; Biological: Low-dose placebo (60-85 years) & Two dose regimen; Biological: Low-dose placebo (60-85 years) & Three dose regimen; Biological: High-dose placebo (60-85 years) & Two dose regimen; Biological: High-dose placebo (60-85 years) & Three dose regimen
Sponsors: Jiangsu Province Centers for Disease Control and Prevention; West China Hospital
Recruiting
Hydrogen Therapy in Patients With Moderate Covid-19 - Condition: Covid-19
Intervention: Drug: Mixture 3,6% H2 in N2 (96.4%)
Sponsor: University Hospital, Grenoble
Not yet recruiting
Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID) - Condition: Covid19
Intervention: Drug: Chloroquine
Sponsor: Fundacion Clinica Valle del Lili
Active, not recruiting
Adaptive COVID-19 Treatment Trial 4 (ACTT-4) - Condition: COVID-19
Interventions: Drug: Baricitinib; Drug: Dexamethasone; Other: Placebo; Drug: Remdesivir
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting
Vitamin D and Zinc Supplementation for Improving Treatment Outcomes Among COVID-19 Patients in India - Condition: COVID-19
Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol); Dietary Supplement: Zinc (zinc gluconate); Dietary Supplement: Zinc (zinc gluconate) & Vitamin D (cholecalciferol); Other: Placebo
Sponsors: Harvard School of Public Health; Foundation for Medical Research; University Health Network, Toronto
Not yet recruiting
Organization of Pulmonary Rehabilitation of Post-COVID-19 Patient With Sequelae (REHABCOVID) - Condition: Covid19
Interventions: Other: Respiratory rehabilitation program (RR).; Other: Respiratory tele-rehabilitation program (TRR).
Sponsor: Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Not yet recruiting
Inhaled Heparin for Hospitalised COVID-19 Patients - Condition: Covid19
Intervention: Drug: Unfractionated heparin
Sponsors: Australian National University; Helwan University; Clinica San Camilo, Argentina
Recruiting
Effect of Vitamin D on Hospitalized Adults With COVID-19 Infection - Condition: Covid19
Interventions: Drug: Cholecalciferol; Other: Placebo
Sponsors: University of Liege; Laboratoires SMB S.A.
Recruiting
Efficacy and Safety of Ovotransferrin in COVID-19 Patients - Condition: Covid19
Intervention: Dietary Supplement: Ovotransferrin
Sponsor: Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo
Not yet recruiting
Study To antagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19 - Condition: Covid19
Interventions: Drug: TM5614; Other: Placebo
Sponsor: Northwestern University
Recruiting
Translation of Mycobacterium Survival Strategy to Develop a Lipo-peptide based Fusion Inhibitor - The entry of enveloped viruses requires the fusion of viral and host cell membranes. An effective fusion inhibitor aiming at impeding such membrane fusion may emerge as a broad-spectrum antiviral agent against a wide range of viral infections. Mycobacterium survives inside the phagosome by inhibiting phagosome-lysosome fusion with the help of a coat protein coronin 1. Structural analysis of coronin 1 and other WD40-repeat protein suggest that the trp-asp (WD) sequence is placed at distorted…
Repurposing Anti-Cancer Drugs for COVID-19 Treatment - The novel coronavirus disease 2019 (COVID-19) pandemic has caused catastrophic damage to human life across the globe along with social and financial hardships. According to the Johns Hopkins University Coronavirus Resource Center, more than 41.3 million people worldwide have been infected, and more than 1,133,000 people have died as of October 22, 2020. At present, there is no available vaccine and a scarcity of efficacious therapies. However, there is tremendous ongoing effort towards…
Gammacoronavirus Avian Infectious Bronchitis Virus and Alphacoronavirus Porcine Epidemic Diarrhea Virus Exploit a Cell-Survival Strategy via Upregulation of cFOS to Promote Viral Replication - Coronaviruses have evolved a variety of strategies to optimize cellular microenvironment for efficient replication. In this study, we report the induction of AP-1 transcription factors by coronavirus infection based on genome-wide analyses of differentially expressed genes in cells infected with avian coronavirus infectious bronchitis virus (IBV). Most members of the AP-1 transcription factors were subsequently found to be upregulated during the course of IBV and porcine epidemic diarrhea virus…
Hypothesis: Alpha-1-antitrypsin is a promising treatment option for COVID-19 - No definitive treatment for COVID-19 exists although promising results have been reported with remdesivir and glucocorticoids. Short of a truly effective preventive or curative vaccine against SARS-CoV-2, it is becoming increasingly clear that multiple pathophysiologic processes seen with COVID-19 as well as SARS-CoV-2 itself should be targeted. Because alpha-1-antitrypsin (AAT) embraces a panoply of biologic activities that may antagonize several pathophysiologic mechanisms induced by…
Development of a nano-luciferase based assay to measure the binding of SARS-CoV-2 spike receptor binding domain to ACE-2 - To identify drugs that could potentially be used to treat infection with SARS-CoV-2, a high throughput 384-well assay was developed to measure the binding of the receptor binding domain (RBD) of the viral S1 protein to its main receptor, angiotensin converting enzyme 2 (ACE2). The RBD was fused to both a HiBIT tag and an IL6 secretion signal to enable facile collection from the cell culture media. The addition of culture media containing this protein, termed HiBIT-RBD, to cells expressing ACE2…
Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network - 12 States, April-August 2020 - Most persons infected with SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), develop virus-specific antibodies within several weeks, but antibody titers might decline over time. Understanding the timeline of antibody decline is important for interpreting SARS-CoV-2 serology results. Serum specimens were collected from a convenience sample of frontline health care personnel at 13 hospitals and tested for antibodies to SARS-CoV-2 during April 3-June 19, 2020, and again…
Bacillus Calmette-Guerin vaccination Policy and Consumption of Ammonium Chloride-Enriched Confectioneries May Be Factors Reducing COVID-19 Death Rates in Europe - CONCLUSIONS: The results seem to confirm an association between BCG-positive vaccination policy and salmiak consumption, and lower death rates from COVID-19. Implementing BCG vaccination policy and fortification of foods with salmiak (NH4Cl) may have a significant impact on the control of SARS-CoV epidemic.
Dysregulated immunity in SARS-CoV-2 infected pregnant women - CONCLUSIONS AND RELEVANCE: SARS-CoV-2 infection during pregnancy was characterized by placental inflammation and reduced antiviral antibody responses, which may impact the efficacy of COVID-19 therapeutics in pregnancy. The long-term implications of placental inflammation for neonatal health also requires greater consideration.
Novel gene-specific translation mechanism of dysregulated, chronic inflammation reveals promising, multifaceted COVID-19 therapeutics - Hyperinflammation and lymphopenia provoked by SARS-CoV-2-activated macrophages contribute to the high mortality of Coronavirus Disease 2019 (COVID-19) patients. Thus, defining host pathways aberrantly activated in patient macrophages is critical for developing effective therapeutics. We discovered that G9a, a histone methyltransferase that is overexpressed in COVID-19 patients with high viral load, activates translation of specific genes that induce hyperinflammation and impairment of T cell…
The Development of a Novel Nanobody Therapeutic for SARS-CoV-2 - Combating the COVID-19 pandemic requires potent and low-cost therapeutics. We identified a novel series of single-domain antibodies (i.e., nanobody), Nanosota-1, from a camelid nanobody phage display library. Structural data showed that Nanosota-1 bound to the oft-hidden receptor-binding domain (RBD) of SARS-CoV-2 spike protein, blocking out viral receptor ACE2. The lead drug possessing an Fc tag ( Nanosota-1C-Fc ) bound to SARS-CoV-2 RBD with a K (d) of 15.7picomolar (∼3000 times more tightly…
One novel virus, different beliefs as playmakers towards disease spread in Africa: looking at COVID-19 from a religious lens - Religious and spiritual observances that draw large people together are pervasive in many parts of the world, including Africa. With the recent emergence of COVID-19, these mass religious gatherings may pose significant threats to human health. Given the compromised healthcare systems in many parts of Africa, faith-based institutions have a huge responsibility towards the management of the potential spread of the virus through effective organizational strategies or interventions. This essay…
Plasma-activated water: An alternative disinfectant for S protein inactivation to prevent SARS-CoV-2 infection - SARS-CoV-2 is a highly contagious virus and is causing a global pandemic. SARS-CoV-2 infection depends on the recognition of and binding to the cellular receptor human angiotensin-converting enzyme 2 (hACE2) through the receptor-binding domain (RBD) of the spike protein, and disruption of this process can effectively inhibit SARS-CoV-2 invasion. Plasma-activated water efficiently inactivates bacteria and bacteriophages by causing damage to biological macromolecules, but its effect on coronavirus…
Inhibiting the reproduction of SARS-CoV-2 through perturbations in human lung cell metabolic network - Viruses rely on their host for reproduction. Here, we made use of genomic and structural information to create a biomass function capturing the amino and nucleic acid requirements of SARS-CoV-2. Incorporating this biomass function into a stoichiometric metabolic model of the human lung cell and applying metabolic flux balance analysis, we identified host-based metabolic perturbations inhibiting SARS-CoV-2 reproduction. Our results highlight reactions in the central metabolism, as well as amino…
Structure of nonstructural protein 1 from SARS-CoV-2 - The periodic emergence of novel coronaviruses (CoVs) represents an ongoing public health concern with significant health and financial burden worldwide. The most recent occurrence originated in the city of Wuhan, China where a novel coronavirus (SARS-CoV-2) emerged causing severe respiratory illness and pneumonia. The continual emergence of novel coronaviruses underscores the importance of developing effective vaccines as well as novel therapeutic options that target either viral functions or…
Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription Complex Reveals an Intermediate State in Cap Synthesis - Transcription of SARS-CoV-2 mRNA requires sequential reactions facilitated by the replication and transcription complex (RTC). Here, we present a structural snapshot of SARS-CoV-2 RTC as it transitions toward cap structure synthesis. We determine the atomic cryo-EM structure of an extended RTC assembled by nsp7-nsp8(2)-nsp12-nsp13(2)-RNA and a single RNA-binding protein, nsp9. Nsp9 binds tightly to nsp12 (RdRp) NiRAN, allowing nsp9 N terminus inserting into the catalytic center of nsp12 NiRAN,…
AN EFFICIENT METHODOLOGY TO MANAGE THE ADMISSIONS IN HOSPITALS DURING THE PANDEMICS SUCH AS COVID 19 -
SARS-CoV-2 예방을 위한 mRNA기반 항원보강제 혼합물 합성 방법 - 본 발명은 SARS-CoV-2(코로나 바이러스) 예방을 위한 mRNA 항원보강제에 관한 것으로 코로나 바이러스에 대한 백신으로서 상기의 항원에 대한 예방을 목적으로 하고 있다. 아이디어에는 보강제에 해당하는 완전프로인트항원보강제(CFA)와 불완전프로인트항원보강제(IFA), 번역과 안정성의 최적화가 된 mRNA, mRNA 운반체, 양이온성 지질 나노입자(lipid nanoparticles)로 구성되며 기존의 백신에 비해 효율성과 안정성의 측면에서 더 향상된 효과를 가지고 있다.
Vorrichtung zum Reinigen und/oder Desinfizieren von Objekten -
Vorrichtung (1) zum Desinfizieren von Objekten mit einer Basiseinheit (2), mit einem Aufnahmebehälter (4) für Wasser, welcher an der Basiseinheit (2) montierbar und von der Basiseinheit demontierbar ist, mit einer Objekthalterung (6) zum Halten und/oder Stützen der Objekte (10), wobei diese Objekthalterung (6) in dem Aufnahmebehälter montierbar ist und mit einer elektrisch betriebenen Reinigungseinrichtung (8), welche in dem Wasser befindliche Objekte zumindest mittelbar reinigt oder desinfiziert, wobei diese Reinigungseinrichtung in der Basiseinheit befindliche Erzeugungsmittel zum Erzeugen einer elektrischen Spannung aufweist sowie einen Plasmagenerator und/oder eine Ultraschallerzeugungseinheit.
wherein the ’ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Lassa virus and Junin virus infections.
Atemschutz-Baukastensystem, das aufweist:
Vorrichtung zur Übergabe von mit Krankheitserregern kontaminierten Gegenständen oder Erzeugnissen nach einer Dekontamination, umfassend eine Einrichtung zur Dekontamination der mit Krankheitserregern kontaminierten Gegenstände oder Erzeugnisse mit mindestens einer UV-Strahlungsquelle (24), eine Durchzugseinrichtung mit Ein- und/oder Ausgabebereichen für die kontaminierten bzw. dekontaminierten Gegenstände oder Erzeugnisse, dadurch gekennzeichnet, dass die Durchzugseinrichtung im Eingang bzw. im Ausgang zum Ein- und/oder Ausgabebereich angeordnete sich paarweise gegenüberliegende Walzen (17) und Räder (4) umfasst, die zum Einzug bzw. zur Ausgabe der kontaminierten bzw. dekontaminierten Gegenstände oder Erzeugnisse vorgesehen sind, wobei die Walzen (17) und die Räder (4) durch im Ein- und/oder Ausgabebereich angeordnete Sensoren (23) und einer elektronische Kontrolleinheit (27) in Bewegung bringbar sind, wobei die Gegenstände oder Erzeugnisse in den Bereich der Einrichtung zur Dekontamination förderbar sind, der zwischen den paarweise angeordneten Walzen (17) und Rädern (4) vorgesehen ist, welcher sich gegenüberliegende Platten (25) aus Quarzglas oder einem UV-transparenten Polymermaterial, wie Graphen oder Kunstglas umfasst, über bzw. unter welchen die UV-Strahlungsquelle (24) angeordnet ist, welche als UVC-LED-Leiste und/oder Modul mit mindestens einer LED-Lampe ausgebildet ist.
제2형 중증급성호흡기증후군 코로나바이러스 감염 질환의 예방 또는 치료용 조성물 - 본 발명은 화학식 1로 표시되는 화합물, 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 제2형 중증급성호흡기증후군 코로나바이러스 감염 질환 예방 또는 치료용 약학적 조성물을 제공한다. [화학식 1] .
JPEG
112020094463686-pat00017.jpg
48
135
新型冠状病毒中和性抗体滴度检测ELISA试剂盒 - 本发明提供一种新型冠状病毒中和性抗体滴度检测ELISA试剂盒,其中包括:包被有生物素‑链霉亲和素标记的人ACE2蛋白的酶标板、辣根过氧化酶标记的新型冠状病毒RBD蛋白、新型冠状病毒中和性抗体阳性对照、包被液、洗涤液、稀释液、封闭液、显色液和终止液等。该试剂盒具有成本低,操作简单,高灵敏度、高特异性、高准确度的特点,可用于新型冠状病毒中和抗体的批量、快速检测。
Reagenzien und Verwendungen zur Diagnose einer SARS-CoV-2-Infektion -
Diagnostisch nützlicher Träger umfassend ein Polypeptid umfassend SEQ ID NO1 oder eine Variante davon, die an einen Antikörper gegen SEQ ID NO1 aus einer Probe von einem Patienten binden kann, der an einer SARS-CoV-2-Infektion leidet, wobei das Polypeptid bevorzugt auf der Festphase des Trägers immobilisiert ist.
Verwendung eines Polypeptides umfassend SEQ ID NO1 oder eine Variante davon, die an einen Antikörper gegen SED ID NO1 aus einer Probe von einem Patienten binden kann, zur Herstellung eines diagnostischen Kits.